Pediatric Rheumatology Online Journal

Vol 2, No. 2  2004

http://www.pedrheumonlinejournal.org

 

PEDIATRIC RHEUMATOLOGY LITERATURE REVIEW FOR 2003: ARTICLES YOU DON’T WANT TO MISS.

 

REGULATORY T CELLS

 

Selected by Troy R. Torgerson MD PhD

University of Washington, Seattle, WA

 

Control of regulatory T cell development by the transcription factor Foxp3.  Hori S, Nomura T, Sakaguchi S:  Science 2003, 299:1057-1061.

 

AND

 

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.  Fontenot JD, Gavin MA, Rudensky AY:  Nat Immunol 2003, 4:330-336.

 

AND

 

An essential role for Scurfin in CD4+CD25+ T regulatory cells.  Khattri R, Cox T, Yasayko SA, Ramsdell F:  Nat Immunol 2003, 4:337-342.

 

 

Significance:  Immune tolerance to self-antigens is induced and maintained by a combination of central and peripheral mechanisms.  Central tolerance is generated primarily in the thymus where autoreactive T cells are either deleted or made anergic.  Tolerance is then maintained in the periphery by special subsets of “Regulatory” T cells (TR) that are capable of suppressing and keeping immune responses in check.  The CD4+CD25+ subset of regulatory T cells appears to be of particular importance. However, the source of these cells and the mechanisms by which they function remain relatively obscure.  These papers provide some initial insight by showing that Foxp3, the gene mutated in the severe, systemic, X-linked autoimmune disorders IPEX (OMIM 304930 in humans) and Scurfy (in mice), is required for the development of CD4+CD25+ TR in mice. These studies not only investigate the mechanism of disease leading to IPEX, but also explore a potential means for re-establishing peripheral tolerance, which may be useful in the control of autoimmune disorders in general.

Findings:  The CD4+CD25+ TR subset makes up approximately 5-10% of the peripheral CD4+ T cell population in most normal mice and humans.  In Scurfy mice, a two base-pair insertion within the Foxp3 gene leads to a frameshift mutation, and this results in a truncated protein product.  The subsequent phenotype suffers from a syndrome of severe autoimmunity characterized by

lymphocytic infiltrates into multiple organs, and death by 3 weeks of age.  These papers show that Scurfy mice lack CD4+CD25+ TR cells, suggesting a role for Foxp3 in the development and possibly the function of this subset.  This role was supported by generation of transgenic mice expressing supranormal levels of Foxp3, which leads to animals with decreased T cell numbers overall but markedly increased percentages of CD4+CD25+ TR cells (15-20% of the CD4+ population) (Khattri et al).

Mating of the Foxp3 transgenic animals to mice lacking CTLA-4 prevented their offspring’s otherwise rapid demise due to an autoimmune lymphoproliferative disorder similar to that of Scurfy mice, thus suggesting that the two pathways may intersect.  Further evidence for Foxp3’s role in the development of CD4+CD25+ TR cells was provided by forcible expression of Foxp3 in naïve CD4+ T cells by retroviral transduction (Hori et al & Fontenot et al.). Cells transduced with Foxp3 developed a surface phenotype similar to endogenous TR cells including expression of CTLA-4 and GITR.  Like endogenous TR cells, they were able to suppress other activated T cells in a cell-contact dependent fashion; however, their effect was not as potent, suggesting that Foxp3 is necessary but not sufficient for development of full regulatory activity.  The most exciting capability of the Foxp3 transduced T cells was their ability to suppress disease when adoptively transferred into mice with autoimmune enteropathy portending a possible role for Foxp3 in gene therapy for autoimmune diseases in the future (Hori et al.).